A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Issue 8 (3rd August 2017)

• Record Type: Journal Article
• Authors: Levine, Oren; Devji, Tahira; Xie, Feng
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 8(2017)
• Page Start: 1765
• Page End: 1767
• Publication Date: 2017-08-03
• Subjects: immune checkpoint inhibitor -- immunotherapy -- immune-related adverse events -- melanoma; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1322241
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Immune checkpoint inhibitors have revolutionized treatment of advanced cutaneous melanoma. This group of novel therapeutic agents differs from other systemic treatments and has necessitated a new approach for several fundamental aspects of clinical practice in oncology. Marked differences in outcomes associated with immune checkpoint inhibitors compared with other systemic therapies has required a new paradigm for prognostication in the setting of advanced melanoma. Distinct patterns of tumor response have required new norms for disease monitoring. A unique spectrum of toxicity is associated with use of immune checkpoint inhibitors which can be severe and refractory. Patients and clinicians must be informed regarding immune-related adverse events, yet in the published literature, there is substantial variability in reporting. As immune checkpoint inhibitors gain a prominent role in cancer treatment, standardization of adverse event reporting will be vital to ensure validity of evidence and to promote safe clinical practice.